Tubulin: The Protein That Hides the Secret to Preventing Alzheimer's and Parkinson's

Alzheimer's is caused by Tau and amyloid aggregating. Parkinson's is caused by alpha-synuclein aggregating. ALS, ataxia, and other neurodegenerative diseases all share a common feature: proteins that should be in order begin to clump into toxic masses. For decades, pharma companies tried to block these clumps. They mostly failed. Now, a new study published in Nature Communications from the Baylor College of Medicine team offers an opposite and simple approach: Instead of blocking toxicity, boost the brain's natural defense—a protein called tubulin.

What are Tau and alpha-synuclein really?

The classic Alzheimer's story: Tau is bad. It forms clumps. The clumps kill neurons. The end.

But this is a partial picture. Tau and alpha-synuclein are proteins that are supposed to be there. In their healthy function:

• Tau: Helps build the "railroads" of brain cells (microtubules). Its role is to stabilize these fibers.
• Alpha-synuclein: Helps synapses work properly, organizing neurotransmitter release.

The problem: When something goes wrong (cellular stress, oxidative damage, aging), they lose their proper function and start to err. They enter a "free-floating" state called biomolecular condensates—liquid clumps. And these clumps tend to turn into solid, toxic aggregates.

The Baylor discovery: Tubulin is the switch

The team led by Prof. Alan Charles Fraun and Prof. Josephine Fraun studied something simple: What causes Tau and alpha-synuclein to choose between a pathological state and a physiological state?

They found that the choice depends on the tubulin—the protein ratio in the cell. When tubulin (the material that makes microtubules) is present in sufficient quantity, Tau and alpha-synuclein attach to it and build healthy railroads. When tubulin is lacking, there is nothing to attach them to, so they enter the condensate state that leads to toxic aggregates.

The problem: In most Alzheimer's patients, there is little tubulin

This was the key discovery. In the brains of Alzheimer's and Parkinson's patients, tubulin levels are significantly low. This is not a symptom of the disease—it may be the cause.

Without enough tubulin:

1. Not enough microtubules are built
2. Tau and alpha-synuclein are "lost," not knowing where to stand
3. They aggregate into liquid condensates
4. The condensates turn into solid aggregates
5. Neurons die

The paradigm shift: Neurodegenerative diseases are not just "more bad Tau," but "less good tubulin".

"It's like asking whether the story is too much rain or too few roofs. Both sides are true, but the solution is different."

Proof: Add tubulin, the aggregates disappeared

The team tested the theory in several experiments:

In test-tube cells

Human cells engineered to express high Tau began producing toxic aggregates. Adding tubulin caused Tau to leave the condensates and attach to healthy microtubules.

In cultured cell studies

Human nerve cells grown from stem cells of Alzheimer's patients showed aggregates. When tubulin was added through genetic techniques, the aggregates dramatically decreased.

In mice

In engineered mice producing human Tau in the brain, adding tubulin reduced aggregates by 50%+ and extended the mice's lifespan.

A new therapeutic strategy

According to the study, there are at least three ways to increase tubulin in the brain:

1. Drugs that promote tubulin production

Genes that produce tubulin can be targeted. Drugs that activate them are currently in development. The first experiments in mice are planned for 2027.

2. Stabilizing existing tubulin

Tubulin breaks down in the brain with age. Drugs like Epothilone D stabilize it. Already tested in mice. Moving to humans in early 2027.

3. Genetics: Gene therapy

Injecting an additional tubulin gene into brain cells using an AAV virus. A more distant but possible approach.

Why is this a big promise?

The reason: The classic approach has failed. Drugs that directly attack amyloid (lecanemab, donanemab) achieve modest aggregate reduction but with significant side effects (brain hemorrhages). Some patients are worse after treatment.

The new approach—raising tubulin—does not attack a bad protein. It restores normal balance. This is similar to treating a hormone deficiency: no need to eliminate the existing hormone, just add more.

What can be done now?

There is no "tubulin" supplement in the world. But there are things that increase tubulin production in the brain:

1. Avoiding drugs that suppress tubulin

Some chemotherapy drugs (vincristine, vinblastine) intentionally work against tubulin. If you receive them, there is an increased risk of cognitive impairment.

2. Vitamin B12

Essential for the synthesis of tubulin-type proteins. B12 deficiency (common in older adults) lowers its production.

3. Omega-3

Has been shown in studies to support tubulin production in the brain.

4. Physical activity

Increases tubulin expression in neurons, part of the benefits of physical activity for the brain.

5. Intermittent fasting

Activates autophagy, which removes damaged tubulin and encourages the creation of new tubulin.

Broad implications

This approach opens a new horizon for treating a whole group of diseases:

• Alzheimer's: via Tau
• Parkinson's: via alpha-synuclein
• ALS: via TDP-43 (also attaches to tubulin)
• "Normal" brain aging: via similar but milder phenomena

If the approach works in humans too, we could get one drug for several diseases. This is rare in medicine.

The bottom line

We stand on the brink of a paradigm shift in neurological medicine. Instead of looking for the enemy (damaged proteins), we begin to look for the friend (protective proteins, like tubulin). This is an optimistic approach. Drugs from Baylor may be in the clinic within 5-7 years. Until then, supportive interventions (nutrition, activity, B12) are the best protection.